Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors reported 23 stocks worth $1.5B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KLRA (17.3%), HTFL (14.8%) and ADRX (9.0%). Compared with Q2 2026, the fund opened new positions in ADRX, TARS and FRNM, added to ALKS and CABA, trimmed HTFL, PHVS and KYTX and sold out of DNTH and UPB.
Latest filing: what Bain Capital Life Sciences Investors did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() KLRA Kailera Therapeutics Inc | $258M | 17.3% | 22.6M | No change | 2 of 8 | |
| 2 | ![]() HTFL Heartflow Inc | $221M | 14.8% | 4.4M | −4M (−47%) | 5 of 8 | |
| 3 | ![]() ADRX Adarx Pharmaceuticals Inc | $134M | 9.0% | 6.7M | New position | 1 of 8 | |
| 4 | ![]() ALKS Alkermes PLC | $128M | 8.6% | 3.2M | +1.2M (+63%) | 3 of 8 | |
| 5 | ![]() NAMS Newamsterdam Pharma Company | $92.6M | 6.2% | 3.8M | No change | 8 of 8 | |
| 6 | ![]() SVRA Savara Inc | $90.8M | 6.1% | 17.6M | No change | 8 of 8 | |
| 7 | ![]() TARS Tarsus Pharmaceuticals Inc | $86.2M | 5.8% | 1.1M | New position | 1 of 8 | |
| 8 | ![]() PHVS Pharvaris N V | $76.9M | 5.2% | 2.5M | −200K (−7%) | 8 of 8 | |
| 9 | ![]() SLDB Solid Biosciences Inc | $70.9M | 4.8% | 9.8M | No change | 8 of 8 | |
| 10 | ![]() OLMA Olema Pharmaceuticals Inc | $61.2M | 4.1% | 7.1M | No change | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Bain Capital Life Sciences Investors 13F FAQ
What does Bain Capital Life Sciences Investors own?
Bain Capital Life Sciences Investors reported 23 stocks worth $1.5B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are KLRA (17.3%), HTFL (14.8%) and ADRX (9.0%). The table above lists every position in the filing (the top 10 without an account).
What did Bain Capital Life Sciences Investors buy and sell in Q3 2026?
Compared with Q2 2026: 4 new positions, 2 added to, 3 trimmed and 2 sold out. New positions include ADRX, TARS and FRNM. It sold all of DNTH and UPB.
When will Bain Capital Life Sciences Investors file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Bain Capital Life Sciences Investors's portfolio worth?
The Q3 2026 filing reports $1.5B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.















